High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer

Prostate

Volumn 71, Issue 3, 2011, Pages 281-288

  Minner, Sarah ^a   Wittmer, Corinna ^a   Graefen, Markus ^a   Salomon, Georg ^a   Steuber, Thomas ^a   Haese, Alexander ^a   Huland, Hartwig ^a   Bokemeyer, Carsten ^a   Yekebas, Emre ^a   Dierlamm, Judith ^a   Balabanov, Stefan ^a   Kilic, Ergin ^a   Wilczak, Waldemar ^a   Simon, Ronald ^a   Sauter, Guido ^a   Schlomm, Thorsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

prognosis; prostate cancer; PSMA; targeted therapy; tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EARLY CANCER; FOLLOW UP; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; TISSUE MICROARRAY;

ADULT; AGED; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 78951476072     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21241     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74-108.
2. Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, Sellers WR, Lengauer C,. Validating cancer drug targets. Nature 2006; 441 (7092): 451-456.
3. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L,. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23 (3): 455-460.
4. Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC,. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol 2009; 32 (4): 338-341.
5. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE,. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004; 10 (10): 3365-3370.
6. Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H,. Prostate stem cell antigen as therapy target: Tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62 (9): 2546-2553.
7. Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR,. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: Final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004; 100 (10): 2125-2131.
8. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI,. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002; 94 (4): 980-986.
9. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED,. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60 (4): 332-337.
10. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ,. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170 (5): 1717-1721.
11. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ,. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004; 64 (21): 7995-8001.
12. Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, Maguire RT,. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998; 159 (6): 2041-2046; discussion 2046-2047.
13. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH,. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22 (13): 2522-2531.
14. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP,. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006; 30 (4): 628-636.
15. Israeli RS, Powell CT, Fair WR, Heston WD,. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53 (2): 227-230.
16. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH,. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58 (18): 4055-4060.
17. Liu J, Kopeckova P, Buhler P, Wolf P, Pan H, Bauer H, Elsasser-Beile U, Kopecek J,. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm 2009; 6 (3): 959-970.
18. Troyer JK, Beckett ML, Wright GL Jr., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62 (5): 552-558.
19. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI,. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008; 26 (13): 2147-2154.
20. Horoszewicz JS, Kawinski E, Murphy GP,. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7 (5B): 927-935.
21. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP,. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998; 82 (11): 2256-2261.
22. Marchal C, Redondo M, Padilla M, Caballero J, Rodrigo I, Garcia J, Quian J, Boswick DG,. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol 2004; 19 (3): 715-718.
23. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV,. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9 (17): 6357-6362.
24. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R,. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48 (2): 326-334.
25. Sweat SD, Pacelli A, Murphy GP, Bostwick DG,. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52 (4): 637-640.
26. Minner S, Jessen B, Stiedenroth L, Köllermann J, Burandt E, Mirlacher M, Erbersdobler A, Fisch M, Brümmendorf TH, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T,. Low level Her2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010; 16 (5): 1553-1560.
27. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A,. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21 (11): 1371-1378.
28. Erbersdobler A, Fritz H, Schnoger S, Graefen M, Hammerer P, Huland H, Henke RP,. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: Differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 2002; 41 (1): 40-46.
29. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP,. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59 (4): 803-806.
30. la Cour JM, Hoj BR, Mollerup J, Simon R, Sauter G, Berchtold MW,. The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol Oncol 2008; 1 (4): 431-439.
31. Dancau AM, Simon R, Mirlacher M, Sauter G,. Tissue microarrays. Methods Mol Biol 2010; 576: 49-60.
32. Kallioniemi OP, Wagner U, Kononen J, Sauter G,. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10 (7): 657-662.
33. Wright GL Jr, Haley C, Beckett ML, et al. Expression of prostate-specific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol Oncol 1995; 1: 18-28.
34. Ghosh A, Heston WD,. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91 (3): 528-539.
35. Rajasekaran AK, Anilkumar G, Christiansen JJ,. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 2005; 288 (5): C975-C981.
36. Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA,. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38 (5): 696-701.
37. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G,. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15 (2): 167-172.
38. Wolf P, Freudenberg N, Buhler P, Alt K, Schultze-Seemann W, Wetterauer U, Elsasser-Beile U,. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2010; 70 (5): 562-569.
39. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C,. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3 (1): 81-85.
40. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB,. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59 (13): 3192-3198.
41. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH,. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57 (17): 3629-3634.
42. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, Bander NH,. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009; 40 (12): 1754-1761.
43. Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, Pomper MG,. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009; 390 (3): 624-629.
44. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW,. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69 (17): 6932-6940.
45. Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U,. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006; 66 (13): 1359-1370.